EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature

Published:2022-04 Issue: Volume:166 Page:94-97
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Copia Sperandio Rubens,Luiza Teixeira Tostes Francinne,Vidal Campregher Paulo,Ribeiro Paes Vitor,Moura Fernando,Schvartsman Gustavo

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference12 articles.

1. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice;Gahr;Br J Cancer.,2013

2. EGFR Fusions as Novel Therapeutic Targets in Lung Cancer;Konduri;Cancer Discov.,2016

3. EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?;Raez;J Thorac Oncol.,2018

4. EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report;Zhu;Lung Cancer.,2018

5. Guan Y, Song Z, Li Y, Guo H, Shi J, Zhang X, et al. Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR-RAD51 Fusion. Oncologist. 2019;24(8):1027-30.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape;Cancer Treatment Reviews;2024-11

2. Complete response to capmatinib in a patient with metastatic lung adenocarcinoma harboring CD47-MET fusion: a case report;The Oncologist;2024-06-04

3. Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO);ESMO Open;2024-06

4. Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report;Frontiers in Oncology;2024-05-06

5. Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy;Frontiers in Oncology;2024-03-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3